Skip to main content
. Author manuscript; available in PMC: 2013 Mar 19.
Published in final edited form as: Cancer Cell. 2012 Sep 11;22(3):318–330. doi: 10.1016/j.ccr.2012.08.001

Figure 3. Ablation of EGFRs has no effect on K-RasG12V driven lung and intestinal tumors.

Figure 3

(A) Survival of RERT;K-RasG12V;Egfr+/+ (solid circles), RERT;K-RasG12V;Egfr+/lox (grey circles) and RERT;K-RasG12V;Egfrlox/lox (open circles) mice treated with a single injection of 4OHT at P21 to induce NSCLCs.

(B) H&E staining and EGFR and pro-surfactant protein C (SPC) immunostaining (IHC) of consecutive paraffin sections showing representative adenocarcinoma lesions from nine month old RERTK-RasG12V mice carrying either (top) wild type Egfr or (bottom) conditional Egfr alleles.

Scale bar represents 50 μm.

(C) Survival of RERT;K-RasG12V;Apclox/lox;Egfr+/+ (solid circles), RERT;K-RasG12V;Apclox/lox;Egfr+/lox (grey circles) and RERT;K-RasG12V;Apclox/lox;Egfrlox/lox (open circles) mice treated with 4OHT (three days per week, for two weeks) at P21 to induce intestinal tumors.

(D) H&E staining and EGFR and β-catenin immunostaininig (IHC) of consecutive paraffin sections showing representative intestinal tumor lesions from two month old RERT;K-RasG12V;Apclox/lox mice carrying either (top) wild type Egfr or (bottom) conditional Egfr alleles.

Scale bar represents 50 μm.